| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,827 |
14,714 |
$681K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,652 |
7,146 |
$498K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,700 |
3,401 |
$312K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
4,674 |
4,340 |
$133K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
788 |
741 |
$61K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,453 |
1,346 |
$59K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
298 |
270 |
$37K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
355 |
341 |
$17K |
| 99000 |
|
2,038 |
1,919 |
$7K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
41 |
37 |
$3K |
| 99215 |
Prolong outpt/office vis |
12 |
12 |
$610.65 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
49 |
45 |
$554.60 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
91 |
81 |
$214.64 |
| 90686 |
|
27 |
25 |
$74.37 |
| 94760 |
|
43 |
39 |
$37.70 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
44 |
41 |
$30.49 |
| 81002 |
|
12 |
12 |
$18.34 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
104 |
97 |
$5.14 |